Switch theme
Sign up to access all valuation multiples
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company’s flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples.
2021
26
LTM Revenue $1.1M
LTM EBITDA n/a
$4.5M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Mainz Biomed has a last 12-month revenue of $1.1M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Mainz Biomed achieved revenue of $0.9M and an EBITDA of -$19.6M.
Mainz Biomed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Mainz Biomed valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.9M | $0.9M | XXX | XXX | XXX |
| Gross Profit | $0.2M | $0.5M | XXX | XXX | XXX |
| Gross Margin | 20% | 57% | XXX | XXX | XXX |
| EBITDA | -$24.6M | -$19.6M | XXX | XXX | XXX |
| EBITDA Margin | -2749% | -2188% | XXX | XXX | XXX |
| Net Profit | -$26.4M | -$26.3M | XXX | XXX | XXX |
| Net Margin | -2947% | -2941% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Mainz Biomed's stock price is $3.
Mainz Biomed has current market cap of $7.5M, and EV of $4.5M.
See Mainz Biomed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.5M | $7.5M | XXX | XXX | XXX | XXX | $-8.84 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Mainz Biomed has market cap of $7.5M and EV of $4.5M.
Mainz Biomed's trades at 4.2x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Mainz Biomed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Mainz Biomed and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $4.5M | XXX | XXX | XXX |
| EV/Revenue | 5.1x | XXX | XXX | XXX |
| EV/EBITDA | -0.2x | XXX | XXX | XXX |
| P/E | -0.3x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -0.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpMainz Biomed's NTM/LTM revenue growth is 5%
Mainz Biomed's revenue per employee for the last fiscal year averaged $34K, while opex per employee averaged $0.7M for the same period.
Over next 12 months, Mainz Biomed's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Mainz Biomed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Mainz Biomed and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 0% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -2188% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -21% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -2183% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $34K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.7M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 525% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 904% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 653% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 2125% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Mainz Biomed acquired XXX companies to date.
Last acquisition by Mainz Biomed was XXXXXXXX, XXXXX XXXXX XXXXXX . Mainz Biomed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Mainz Biomed founded? | Mainz Biomed was founded in 2021. |
| Where is Mainz Biomed headquartered? | Mainz Biomed is headquartered in United States of America. |
| How many employees does Mainz Biomed have? | As of today, Mainz Biomed has 26 employees. |
| Who is the CEO of Mainz Biomed? | Mainz Biomed's CEO is Mr. Guido Baechler. |
| Is Mainz Biomed publicy listed? | Yes, Mainz Biomed is a public company listed on NAS. |
| What is the stock symbol of Mainz Biomed? | Mainz Biomed trades under MYNZ ticker. |
| When did Mainz Biomed go public? | Mainz Biomed went public in 2021. |
| Who are competitors of Mainz Biomed? | Similar companies to Mainz Biomed include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Mainz Biomed? | Mainz Biomed's current market cap is $7.5M |
| What is the current revenue of Mainz Biomed? | Mainz Biomed's last 12-month revenue is $1.1M. |
| What is the current EV/Revenue multiple of Mainz Biomed? | Current revenue multiple of Mainz Biomed is 4.2x. |
| What is the current revenue growth of Mainz Biomed? | Mainz Biomed revenue growth between 2023 and 2024 was 0%. |
| Is Mainz Biomed profitable? | Yes, Mainz Biomed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
